(Q42437484)

31 October 2017

title

Sample size for biomarker studies: more subjects or more measurements per subject? (English)

1 reference

31 October 2017

0 references

Dejian Lai

1

1 reference

31 October 2017

Terri M King

series ordinal

2

1 reference

31 October 2017

Lemuel A Moyé

series ordinal

3

1 reference

31 October 2017

Qingyi Wei

series ordinal

4

1 reference

31 October 2017

publication date

1 March 2003

1 reference

31 October 2017

published in

Annals of Epidemiology

1 reference

31 October 2017

volume

13

1 reference

31 October 2017

issue

3

1 reference

31 October 2017

page(s)

204-208

1 reference

DNA repair and aging in basal cell carcinoma: a molecular epidemiology study

31 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1047-2797%2802%2900261-2

7 January 2021

Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1047-2797%2802%2900261-2

7 January 2021

Central laboratory sampling plans and quality control in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1047-2797%2802%2900261-2

7 January 2021

Design issues in cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS1047-2797%2802%2900261-2

7 January 2021

Design issues in case-control studies

1 reference

https://api.crossref.org/works/10.1016%2FS1047-2797%2802%2900261-2

7 January 2021

Sample size determination in epidemiologic studies

1 reference

https://api.crossref.org/works/10.1016%2FS1047-2797%2802%2900261-2

7 January 2021

Estimating sample sizes for repeated measurement designs

1 reference

https://api.crossref.org/works/10.1016%2FS1047-2797%2802%2900261-2

7 January 2021

Sample size estimation using repeated measurements on biomarkers as outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1047-2797%2802%2900261-2

7 January 2021

Designing a cost-effective clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-2797%2802%2900261-2

7 January 2021

Statistical power and optimal design for multisite randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-2797%2802%2900261-2

7 January 2021

Sample sizes for phase II clinical trials derived from Bayesian decision theory.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-2797%2802%2900261-2

7 January 2021

10.1016/S1047-2797(02)00261-2

Identifiers

DOI

1 reference

31 October 2017

1 reference